• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study.

作者信息

Thaçi Diamant, Puig Lluís, Reich Kristian, Tsai Tsen-Fang, Tyring Stephen, Kingo Külli, Ziv Michael, Pinter Andreas, Vender Ronald, Lacombe Aude, Xia Summer, Bhosekar Vaishali, Gilloteau Isabelle, Guana Adriana, Blauvelt Andrew

机构信息

Research Institute and Comprehensive Center for Inflammation Medicine, University of Luebeck, Luebeck, Germany.

Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.

出版信息

J Am Acad Dermatol. 2019 Dec;81(6):1405-1409. doi: 10.1016/j.jaad.2019.04.045. Epub 2019 Aug 6.

DOI:10.1016/j.jaad.2019.04.045
PMID:31399223
Abstract
摘要

相似文献

1
Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study.司库奇尤单抗在治疗中度至重度银屑病患者中，通过两年治疗展现出持续清除皮肤症状及改善患者报告结局的疗效：CLEAR研究结果
J Am Acad Dermatol. 2019 Dec;81(6):1405-1409. doi: 10.1016/j.jaad.2019.04.045. Epub 2019 Aug 6.
2
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.司库奇尤单抗在清除中重度斑块型银屑病患者皮肤方面优于乌司奴单抗：来自 CLEAR 研究的结果。
J Am Acad Dermatol. 2017 Jan;76(1):60-69.e9. doi: 10.1016/j.jaad.2016.08.008. Epub 2016 Sep 20.
3
Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.司库奇尤单抗在中重度斑块型银屑病患者中比乌司奴单抗更能持续改善日常活动和人际关系：CLEAR 研究 52 周结果。
J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1693-1699. doi: 10.1111/jdv.14391. Epub 2017 Aug 8.
4
Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.司库奇尤单抗在清除亚洲中重度斑块型银屑病患者的皮肤方面优于乌司奴单抗：来自 CLEAR 研究的亚组分析。
J Dermatol. 2019 Sep;46(9):752-758. doi: 10.1111/1346-8138.15004. Epub 2019 Jul 25.
5
Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study.司库奇尤单抗对生活质量和银屑病相关症状的影响：CLEAR 52 周研究中与乌司奴单抗的对比分析。
J Am Acad Dermatol. 2018 Apr;78(4):741-748. doi: 10.1016/j.jaad.2017.10.025. Epub 2017 Oct 21.
6
Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY).司库奇尤单抗在清除皮肤和改善中重度斑块型银屑病患者生活质量方面优于乌司奴单抗：一项为期 52 周的双盲 3b 期试验（CLARITY）的结果。
J Eur Acad Dermatol Venereol. 2021 Jan;35(1):135-142. doi: 10.1111/jdv.16558. Epub 2020 Jun 8.
7
Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.乌司奴单抗治疗重度复杂性红皮病型银屑病：快速清除、安全性及持续缓解
Dermatol Ther. 2014 Sep-Oct;27(5):257-9. doi: 10.1111/dth.12131. Epub 2014 May 9.
8
Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.司库奇尤单抗应答不足的银屑病患者中布罗达umab 的疗效和安全性：两项随机 III 期试验的亚组分析。
Br J Dermatol. 2019 Feb;180(2):306-314. doi: 10.1111/bjd.17318. Epub 2018 Dec 27.
9
Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.在英国，以司库奇尤单抗为对照，优时比单抗序贯生物治疗作为中重度银屑病一线治疗的成本效益分析
J Med Econ. 2018 Aug;21(8):810-820. doi: 10.1080/13696998.2018.1474747. Epub 2018 Jun 6.
10
Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.在一项随机、双盲的 3b 期临床试验中，与乌司奴单抗相比，接受依奇珠单抗治疗的中重度银屑病患者在 52 周时累积获益更大。
J Dermatolog Treat. 2020 Mar;31(2):141-146. doi: 10.1080/09546634.2019.1587146. Epub 2019 Mar 18.

引用本文的文献

1
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.司库奇尤单抗剂量递增治疗中重度斑块状银屑病患者的疗效和安全性：来自 PURE 登记研究的数据。
Arch Dermatol Res. 2024 Jun 8;316(7):362. doi: 10.1007/s00403-024-03122-w.
2
Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection.在乙型肝炎或丙型肝炎感染的真实世界环境中，用司库奇尤单抗治疗银屑病的患者中肝炎病毒再激活。
Clin Drug Investig. 2022 Jun;42(6):525-531. doi: 10.1007/s40261-022-01163-5. Epub 2022 May 28.
3
Epidemiological survey of the psoriasis patients in the Japanese Society for Psoriasis Research from 2013 to 2018.
2013 年至 2018 年日本银屑病研究学会银屑病患者的流行病学调查。
J Dermatol. 2021 Jun;48(6):864-875. doi: 10.1111/1346-8138.15803. Epub 2021 Feb 13.
4
Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study.司库奇尤单抗改善中重度银屑病患者的焦虑和抑郁：SUPREME 研究的事后分析。
Acta Derm Venereol. 2021 Mar 31;101(3):adv00422. doi: 10.2340/00015555-3712.
5
Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.司库奇尤单抗治疗银屑病、银屑病关节炎或强直性脊柱炎患者结核再激活的相关性。
JAMA Dermatol. 2021 Jan 1;157(1):43-51. doi: 10.1001/jamadermatol.2020.3257.